Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
Open Access
- 4 September 2017
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 17 (1) , 1-5
Abstract
Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence. Patients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients’ adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6. Of 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant (n = 33) and non-compliant groups (n = 20) (p = 0.00001). Older age, greater disability, patient’s perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists’ estimations of adherence were all positively associated with treatment adherence. We showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using.Keywords
Funding Information
- Merck KGaA
This publication has 20 references indexed in Scilit:
- Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic ReviewPLOS ONE, 2015
- How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosisExpert Opinion on Drug Delivery, 2015
- Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort StudyPLOS ONE, 2015
- Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART studyExpert Opinion on Drug Delivery, 2015
- Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple SclerosisJournal of Managed Care Pharmacy, 2013
- Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United StatesAnnals of Internal Medicine, 2012
- RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherenceExpert Opinion on Drug Delivery, 2012
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 2010
- Impact of Adherence to Interferons in the Treatment of Multiple SclerosisClinical Drug Investigation, 2010
- Eighteenth Meeting of the European Neurological Society 7–11 June 2008, Nice, FranceJournal of Neurology, 2008